Biopsy Practices in DLBCL

August 15, 2024

Opinion

Video

Carla Casulo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide clinical insights on biopsy practices and discuss the importance of cell of origin in treating diffuse large B-cell lymphoma (DLBCL).

Now Viewing

EP: 1.Biopsy Practices in DLBCL

EP: 2.First-Line Treatment of Stage I/II DLBCL

EP: 3.Treatment Practices for Stage III/IV DLBCL

EP: 4.Treatment Algorithm for Relapsed/Refractory DLBCL

EP: 5.Adverse Event Considerations in DLBCL

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Recent Videos

Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.

Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.

$Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.$